Sodium Fusidate Oral: A Bacterial Protein Synthesis Inhibitor by Preventing the Turnover Ofelongation Factor G (EF-G) from the Ribosome - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com
Retrieved on:
Wednesday, April 7, 2021
"SODIUM FUSIDATE ORAL - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prosthetic Joint Infection in 7 Major Markets.
Key Points:
- "SODIUM FUSIDATE ORAL - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prosthetic Joint Infection in 7 Major Markets.
- Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
- Sodium Fusidate oral, (also known as Fusidic acid, FA or sodium fusidate) acts as a bacterial protein synthesis inhibitor by preventing the turnover ofelongation factor G (EF-G) from the ribosome.
- What are the other emerging products available and how these are giving competition to SODIUM FUSIDATE ORAL?